| scholarly article | Q13442814 |
| P356 | DOI | 10.1158/0008-5472.CAN-04-2045 |
| P698 | PubMed publication ID | 15548683 |
| P50 | author | Kenneth P Nephew | Q91963229 |
| P2093 | author name string | Pearlly S Yan | |
| Wade V Welshons | |||
| Christoph Plass | |||
| Edward M Curran | |||
| Meiyun Fan | |||
| Victor X Jin | |||
| Ramana V Davuluri | |||
| Tim H-M Huang | |||
| Yu-Wei Leu | |||
| Joseph C Liu | |||
| Susan H Wei | |||
| P433 | issue | 22 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 8184-8192 | |
| P577 | publication date | 2004-11-01 | |
| P1433 | published in | Cancer Research | Q326097 |
| P1476 | title | Loss of estrogen receptor signaling triggers epigenetic silencing of downstream targets in breast cancer | |
| P478 | volume | 64 |
| Q38720232 | A New Role for ERα: Silencing via DNA Methylation of Basal, Stem Cell, and EMT Genes |
| Q40081216 | A Retrospective Study on the Efficacy of Trastuzumab in HER2-Positive and Tamoxifen-Refractory Breast Cancer with Brain Metastasis |
| Q64260538 | A two-gene epigenetic signature for the prediction of response to neoadjuvant chemotherapy in triple-negative breast cancer patients |
| Q36994934 | AKT alters genome-wide estrogen receptor alpha binding and impacts estrogen signaling in breast cancer. |
| Q21092374 | Aberrant DNA methylation of OLIG1, a novel prognostic factor in non-small cell lung cancer |
| Q35985483 | Aberrant TGFβ/SMAD4 signaling contributes to epigenetic silencing of a putative tumor suppressor, RunX1T1 in ovarian cancer |
| Q33417274 | Aberrant epigenetic silencing is triggered by a transient reduction in gene expression |
| Q34534410 | Aberrant methylation of Reprimo correlates with genetic instability and predicts poor prognosis in pancreatic ductal adenocarcinoma |
| Q36840255 | Aberrant transforming growth factor beta1 signaling and SMAD4 nuclear translocation confer epigenetic repression of ADAM19 in ovarian cancer |
| Q35605714 | Adipocyte hypoxia promotes epithelial-mesenchymal transition-related gene expression and estrogen receptor-negative phenotype in breast cancer cells |
| Q33363087 | An Sp1/Sp3 binding polymorphism confers methylation protection. |
| Q34497012 | An integrated analysis of SOCS1 down-regulation in HBV infection-related hepatocellular carcinoma |
| Q34042332 | An unusual function of RON receptor tyrosine kinase as a transcriptional regulator in cooperation with EGFR in human cancer cells |
| Q54208544 | Association of promoter methylation of ERα and ERβ with sporadic breast cancer--a study from North India. |
| Q38843250 | Beyond transcription factors: how oncogenic signalling reshapes the epigenetic landscape |
| Q33652855 | Breast cancer-associated fibroblasts confer AKT1-mediated epigenetic silencing of Cystatin M in epithelial cells |
| Q37472631 | Cancer epigenetics: a perspective on the role of DNA methylation in acquired endocrine resistance |
| Q36157132 | Changes in DNA methylation are associated with the development of drug resistance in cervical cancer cells |
| Q38067765 | Chromatin landscape and endocrine response in breast cancer. |
| Q34080232 | Chromatin remodeling in mammary gland differentiation and breast tumorigenesis |
| Q34613588 | Cystatin M loss is associated with the losses of estrogen receptor, progesterone receptor, and HER4 in invasive breast cancer |
| Q35009790 | DNA hypermethylation of ESR1 and PGR in breast cancer: pathologic and epidemiologic associations |
| Q24644027 | DNA methylation represses IFN-gamma-induced and signal transducer and activator of transcription 1-mediated IFN regulatory factor 8 activation in colon carcinoma cells |
| Q52025811 | Developmental biology: two paths to silence merge. |
| Q35221939 | Differential effects of continuous and intermittent 17beta-estradiol replacement and tamoxifen therapy on the prevention of glomerulosclerosis: modulation of the mesangial cell phenotype in vivo |
| Q24641991 | Differential estradiol and selective estrogen receptor modulator (SERM) regulation of Keratin 13 gene expression and its underlying mechanism in breast cancer cells |
| Q33285707 | Diverse histone modifications on histone 3 lysine 9 and their relation to DNA methylation in specifying gene silencing |
| Q36287377 | Downregulation of death-associated protein kinase 1 (DAPK1) in chronic lymphocytic leukemia |
| Q40006128 | Eliminating epigenetic barriers induces transient hormone-regulated gene expression in estrogen receptor negative breast cancer cells |
| Q28390582 | Enriched transcription factor binding sites in hypermethylated gene promoters in drug resistant cancer cells |
| Q37429943 | Environmental estrogens differentially engage the histone methyltransferase EZH2 to increase risk of uterine tumorigenesis |
| Q36337694 | Epigenetic Therapy in Breast Cancer |
| Q37324446 | Epigenetic alterations in the breast: Implications for breast cancer detection, prognosis and treatment |
| Q24652017 | Epigenetic changes during disease progression in a murine model of human chronic lymphocytic leukemia |
| Q36109306 | Epigenetic changes in virus-associated human cancers. |
| Q34119133 | Epigenetic changes of CXCR4 and its ligand CXCL12 as prognostic factors for sporadic breast cancer |
| Q36614480 | Epigenetic inactivation of TCF2 in ovarian cancer and various cancer cell lines |
| Q37962586 | Epigenetic modulation: a novel therapeutic target for overcoming hormonal therapy resistance |
| Q27694612 | Epigenetic regulation in estrogen receptor positive breast cancer--role in treatment response |
| Q37688699 | Epigenetic regulation of endometrium during the menstrual cycle. |
| Q36891892 | Epigenetic regulation of estrogen signaling in breast cancer |
| Q39739549 | Epigenetic regulation of the ERbeta gene on the estrogen signal transfection pathway in colon cancer cells |
| Q33629585 | Epigenetic setting for long-term expression of estrogen receptor α and androgen receptor in cells. |
| Q34621606 | Epigenetic silencing mediated through activated PI3K/AKT signaling in breast cancer |
| Q36856318 | Epigenetic targeting in breast cancer: therapeutic impact and future direction |
| Q38012175 | Epigenetics of estrogen receptor-negative primary breast cancer |
| Q37078784 | Epigenomics and breast cancer |
| Q33352027 | Epigenotyping in peripheral blood cell DNA and breast cancer risk: a proof of principle study |
| Q38811244 | Estradiol differentially induces progesterone receptor isoforms expression through alternative promoter regulation in a mouse embryonic hypothalamic cell line |
| Q36787353 | Estrogen receptor and HER2/neu status affect epigenetic differences of tumor-related genes in primary breast tumors. |
| Q33797076 | Estrogen receptor-alpha methylation predicts melanoma progression |
| Q33881333 | Estrogen-mediated epigenetic repression of large chromosomal regions through DNA looping |
| Q37106891 | Estrogen-mediated suppression of the gene encoding protein tyrosine phosphatase PTPRO in human breast cancer: mechanism and role in tamoxifen sensitivity |
| Q37310981 | Familial and racial determinants of tumour suppressor genes promoter hypermethylation in breast tissues from healthy women. |
| Q34600622 | Functional characterization of Trip10 in cancer cell growth and survival. |
| Q33355172 | Genome-wide analysis of alternative promoters of human genes using a custom promoter tiling array |
| Q53669221 | HDAC inhibition does not induce estrogen receptor in human triple-negative breast cancer cell lines and patient-derived xenografts. |
| Q31097091 | Heritable clustering and pathway discovery in breast cancer integrating epigenetic and phenotypic data |
| Q39707882 | Hypermethylation of the progesterone receptor A in constitutive antiprogestin-resistant mouse mammary carcinomas. |
| Q47247432 | Hypermethylation pattern of ESR and PgR genes and lacking estrogen and progesterone receptors in human breast cancer tumors: ER/PR subtypes |
| Q33754130 | Identifying estrogen receptor alpha target genes using integrated computational genomics and chromatin immunoprecipitation microarray |
| Q33774643 | Inference of hierarchical regulatory network of estrogen-dependent breast cancer through ChIP-based data |
| Q54410902 | Let-7a regulation of insulin-like growth factors in breast cancer. |
| Q37276323 | Luminal breast cancer metastasis is dependent on estrogen signaling |
| Q39079170 | MMASS: an optimized array-based method for assessing CpG island methylation |
| Q36141628 | Mapping of genetic and epigenetic regulatory networks using microarrays |
| Q35176381 | MicroRNA regulation of molecular pathways as a generic mechanism and as a core disease phenotype |
| Q49716199 | Preliminary Study of the Role F-Box Protein 32 (FBXO32) in Colorectal Neoplasms Through the Transforming Growth Factor beta (TGF-β)/Smad4 Signalling Pathway. |
| Q37639114 | Progesterone receptor isoform-specific promoter methylation: association of PRA promoter methylation with worse outcome in breast cancer patients |
| Q33231756 | Quantitative assessment of DNA methylation: Potential applications for disease diagnosis, classification, and prognosis in clinical settings |
| Q37160674 | Search for genetic markers and functional variants involved in the development of opiate and cocaine addiction and treatment |
| Q33527153 | Simultaneous CXCL12 and ESR1 CpG island hypermethylation correlates with poor prognosis in sporadic breast cancer |
| Q36937053 | Sustained induction of epithelial to mesenchymal transition activates DNA methylation of genes silenced in basal-like breast cancers |
| Q34654640 | Systematic dissection of the mechanisms underlying progesterone receptor downregulation in endometrial cancer |
| Q37798252 | TGF-β: friend or foe? The role of TGF-β/SMAD signaling in epigenetic silencing of ovarian cancer and its implication in epigenetic therapy. |
| Q28481232 | Tamoxifen-induced epigenetic silencing of oestrogen-regulated genes in anti-hormone resistant breast cancer |
| Q39646436 | Targeted methylation of CMV and E1A viral promoters |
| Q39971057 | Targeted screening of SiRNA directed HBV polymerase gene for effective inhibition of HBV expression |
| Q26782620 | The dark side of ZNF217, a key regulator of tumorigenesis with powerful biomarker value |
| Q34193554 | The influence of cis-regulatory elements on DNA methylation fidelity |
| Q80635200 | The interactions between GPR30 and the major biomarkers in infiltrating ductal carcinoma of the breast in an Asian population |
| Q34408630 | The many faces of estrogen signaling. |
| Q91970091 | The potential influence of breast cancer estrogen receptors' distribution on active DNA demethylation |
| Q36261732 | The prima donna of epigenetics: the regulation of gene expression by DNA methylation |
| Q40269139 | Tumor suppressor p16INK4A regulates polycomb-mediated DNA hypermethylation in human mammary epithelial cells. |
| Q34135741 | Viral hit and run-oncogenesis: Genetic and epigenetic scenarios |
| Q24634687 | Xenoestrogen-induced epigenetic repression of microRNA-9-3 in breast epithelial cells |
| Q33853052 | Xenoestrogen-induced regulation of EZH2 and histone methylation via estrogen receptor signaling to PI3K/AKT. |
| Q59134234 | and Methylation Attenuates Tubulin Expression and Cell Stiffness in Cancer |
Search more.